Biopharmaceutical Development and GMP Manufacturing August 2012

Kai Pohlmeyer

August 1, 2012

1 Min Read

BPI_A_121007AR16_O_182722b.jpg

Richter-Helm has more than 25 years of experience in the development and good manufacturing practice (GMP)–compliant production of a wide range of biopharmaceuticals, including

  • recombinant proteins (e.g., cytokines, growth factors, antibody fragments, surface antigens)

  • plasmid DNA

  • microbial vaccines (e.g., attenuated whole cell vaccines).

Customized Solutions

Richter-Helm offers customized solutions for all steps in biopharmaceutical projects through contract development and manufacturing services featuring

  • GMP state-of-the-art facilities for microbial production

  • fermentor scale up to 1,500 L

  • strong expertise in Escherichia coli and yeast (e.g., Pichia)

  • preclinical/clinical trials to market supply at a large scale.

BPI_A_121007AR16_O_182723b.jpg

BPI_A_121007AR16_O_182724b.jpg

Out-licensing

Richter-Helm out-licenses its own biosimilar developments in

  • women’s health (osteoporosis)

  • infectious diseases (hepatitis).

Active Pharmacetical Ingredients

Sales of active pharmaceutical ingredients

  • Teriparatide

  • IFN alpha 2a.

Fill–Finish

Full fill and finish operation will begin in 2013 and will feature

  • 1,100 m2 cleanroom

  • two filling lines built according to the latest regulatory requirements (syringe and vial/cartridge/lyophilisation line)

  • labeling machines

  • unbuilt cleanroom area 130 m2 for expansion

  • special room for small batches.

About the Author

Author Details
Dr. Kai Pohlmeyer is head of business development, +49-40-2375-2430, [email protected].

You May Also Like